Gemmer Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Gemmer Asset Management’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-151	Closed	-$1K	–	1307
2017 Q2	$1K	Hold	151	–	–	﹤0.01%	1236
2017 Q1	$1K	Hold	151	–	–	﹤0.01%	1220
2016 Q4	$1K	Hold	151	–	–	﹤0.01%	1202
2016 Q3	$1K	Hold	151	–	–	﹤0.01%	1211
2016 Q2	$1K	Hold	151	–	–	﹤0.01%	1226
2016 Q1	$0	Hold	151	–	–	﹤0.01%	1331
2015 Q4	$1K	Hold	151	–	–	﹤0.01%	1250
2015 Q3	$1K	Hold	151	–	–	﹤0.01%	1240
2015 Q2	$2K	Sell	151 -35	-19%	-$375	﹤0.01%	1206
2015 Q1	$2K	Buy	186 +35	+23%	+$450	﹤0.01%	1244
2014 Q4	$2K	Hold	151	–	–	﹤0.01%	1205
2014 Q3	$2K	Hold	151	–	–	﹤0.01%	1206
2014 Q2	$2K	Hold	151	–	–	﹤0.01%	1236
2014 Q1	$3K	Buy	+151	New	+$2.28K	﹤0.01%	1100

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

CLM

ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Gemmer Asset Management's KERX Position: Q3 2017 in Review

Gemmer Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2017, closing a stake of 151 shares — an estimated $1K sold.

Gemmer Asset Management first reported a position in KERX in Q1 2014 and held it in 14 quarters. The position peaked at $3K in Q1 2014. 132 funds tracked by Wall St. Rank hold KERX as of Q3 2017.

Gemmer Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
Gemmer Asset Management sold 151 Keryx Biopharmaceuticals Inc shares in Q3 2017, an estimated $1K.
Gemmer Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q1 2014 and held it in 14 quarters.
Gemmer Asset Management's Keryx Biopharmaceuticals Inc position peaked at $3K in Q1 2014.
132 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2017.

Based on Gemmer Asset Management's 13F filing for Q3 2017, filed 12 Oct 2017.